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Sickle cell disease is a genetic mutation of hemoglobin in red blood cells that 
causes them to become more rigid, aggregate and block blood vessels, and also to 
prematurely lyse and die releasing inflammatory contents into the blood. Unfortunately, 
11% of children with sickle cell disease suffer a stroke before the age of 20, with children 
between the ages of 2-5 being the most vulnerable. Upon clinical examination of these 
stroke lesions, there are signs of arterial remodeling through enzymatic degradation of the 
elastic lamina. Our lab has shown previously that TNFα stimulation or peripheral blood 
mononuclear cells from people with sickle cell disease can induce the expression and 
activity of the potent elastase and collagenase cathepsin K in human aortic endothelial 
cells. Given these promising results, here we present data on cathepsin K inhibition as a 
novel therapeutic target for the reduction of the elastic lamina degradation in arteries in a 
mouse model of sickle cell disease.  
SS and AS mice were bred using the offspring of an SS male and an AS female 
Towne’s transgenic mouse model. After weaning, three week old AS and SS mice were 
given 6mg/kg intraperitoneal injections of odanacatib daily for 10 weeks. Mice were 
euthanized, and the carotid arteries, aorta, and brain were isolated. The carotid arteries 
were used for histological studies of elastin by Van Giesen staining, and immunostaining 
for cathepsin K. Cathepsin K staining was elevated in the SS mice receiving saline 
injections compared to littermate AS controls, and treatment with cathepsin K inhibitor 
did not change the intensity of the staining. However, elastin staining showed that 
cathepsin K inhibition significantly reduced the number of fragmentations in the elastin 
within the arterial wall. This suggests that odanacatib is effectively reducing cathepsin K 
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activity in the arterial wall, and this is correlated with a significant reduction in elastic 
lamina fragmentation in these mice. 
Proteolytic degradation of elastic lamina is a key signal for smooth muscle cell 
migration and luminal narrowing, and our demonstration here that elevated cathepsin K 
in sickle cell transgenic mice can be reduced by cathepsin K inhibition presents a novel 
mechanism to target accelerated arterial remodeling in children with sickle cell disease at 







Sickle cell disease is a genetic mutation of the hemoglobin in red blood cells that causes 
them to become more rigid and crescent shaped. Although the mutation only directly 
affects red blood cells, sickle cell disease negatively impacts nearly every tissue system 
in the body. Specifically, 11% of children with sickle cell disease suffer a stroke before 
the age of 20, with children between the ages of 2-5 being the most vulnerable1. Upon 
clinical examination of these stroke lesions, signs of arterial remodeling, similar to the 
type of remodeling seen in atherosclerosis, are apparent. 
Remodeling is initiated when circulating inflammatory factors promote adhesion of 
circulating monocytes and their subsequent extravasation, or movement beneath the 
endothelial layer, cause destruction of the elastic lamina, which eventually results in the 
narrowing of the artery2, 3. Enzymatic degradation of the elastic lamina is accomplished 
through powerful proteases, especially cathepsin K, which plays a particular role in the 
realm of arterial remodeling as it represents the most powerful mammalian elastase yet 
identified having the ability to degrade the elastin within the arterial wall4. 
People with sickle cell disease are especially at risk for cathepsin-mediated arterial 
remodeling because they have chronically elevated plasma levels of tumor necrosis factor 
(TNFα) and other inflammatory factors which leads to increased monocyte adhesion to 
the endothelial surface throughout the vasculature5. In the field of biomedical 
engineering, our lab has shown that TNFα stimulation upregulates cathepsin K in human 
aortic endothelial cells (HAECs) through the JNK/c-Jun signaling axis as evidenced by 
reduction in cathepsin K activity when the kinase, JNK, was inhibited6. Due to the major 
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role that cathepsin K plays in arterial remodeling, we want to investigate its potential as a 
novel therapeutic target for the reduction of sickle cell stroke risk in vivo. 
Our lab uses the Townes knock-out/knock-in transgenic mouse model of sickle cell 
disease that expresses human hemoglobin with the sickle mutation. One specific point of 
interest in vivo is the branching between the left and right carotid arteries because this is 
where arterial remodeling is observed in people with sickle cell disease7. Excessive 
remodeling of these arteries can be fatal, as it would cut off circulation to the brain. 
Consequently, it is important to be able to apply the correlation between TNFα and 
cathepsin K to restore normal arterial structure in the context of sickle cell disease. 
Currently, the only known method to reduce the risk of stroke is routine blood 
transfusion; however, this is not a solution, a quick fix that causes these children great 
distress. Consequently, this study aims to identify a potential drug target to provide a 
better treatment option for these children. In general, Odanacatib is a newly developed 
cathepsin K inhibitor currently in phase III trials to treat osteoporosis8. This drug will be 
used in vivo on sickle transgenic mice to inhibit cathepsin K activity within the arterial 
walls, which we hypothesize will decrease elastin degradation. This is important because 
by successfully abrogating cathepsin activity and restoring arterial structure, the risk of 








 Sickle cell disease is a genetic disorder characterized by “crescent” shaped red 
blood cells. The genetic code is altered by a point mutation changing an adenosine to a 
thymine, consequently replacing a glutamic acid with a valine in the sixth position of the 
amino acid sequence of each beta hemoglobin9. This is a dangerous substitution because 
glutamic acid and valine have very different properties. Glutamic acid is negatively 
charged and hydrophilic while valine is neutral and hydrophobic. While oxygenated, this 
mutation is irrelevant; however, upon deoxygenation there is a conformational change 
that exposes the valine to the hydrophilic environment10. Due to hydrophobic 
interactions, the exposed valine finds other exposed valines to reduce energy within the 
system. This is what leads to the formation of sickle hemoglobin polymers that are stiff, 
which distorts the biconcave disc shape of red blood cells11. This process repeats every 
cardiac cycle, and the periodic stress that this puts on the red blood cell significantly 
reduces its life span.  
Although the mutation is of the beta hemoglobin in red blood cells, there are several 
repercussions that affect most organs and tissues in the body. One such repercussion is 
elevated inflammatory and adhesion factors. Adhesion factors include intercellular 
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-
selectin while inflammatory factors include tumor necrosis factor alpha (TNFα) and 
interleukin-1 (IL-1)12. The combination of these factors lead to red blood cell adhesion to 
the endothelium and vaso-occlusions in the micro-vasculature13. This is the cause of the 
painful crisis that many sickle patients experience in their life time.   
However, these vaso-occlusions do not explain the fact that there is over a 200 percent 
increase in risk of stroke, which is caused by impaired blood flow in the carotid arteries14. 
The risk of stroke is greatest in children between 2 and 5 year old14. Normally, strokes 
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have physical symptoms such as face drooping, muscle weakness, and impaired speech. 
However, about 17-35% of children who experience strokes, instead experience silent 
strokes15. These types of strokes don’t have the same physical symptoms, and instead 
result in the death of parts of the brain, which may manifest itself in learning disabilities 
later in life16. 
When examined clinically, these stroke lesions indicate the presence of extensive arterial 
remodeling, which cuts off blood supply to the brain17. Loss of blood flow to the brain is 
caused by a blockage in the carotid arteries leading to ischemia, or low oxygen supply, in 
parts of the brain. These blockages primarily develop in three ways: aggregations of 
blood cells, lack of vasodilation, and arterial wall thickening. Aggregations of blood cells 
noticeably impair blood flow only in the microvascular where vessels are a few cells 
wide. That is why this does not explain impaired blood flow in the larger carotid arteries, 
which are about 6mm in diameter. Lack of vasodilation is promoted by hemoglobin’s 
affinity for nitric oxide (NO) in the blood. Since sickle cells are constantly undergoing 
cyclic deformation, they tend to lyse and spill their intracellular into the bloodstream. The 
free hemoglobin then is able to bind to NO, preventing it from binding to the endothelium 
and subsequent signaling for vasodilation14. While this accelerates the impairment of 
blood flow, the main contributor is arterial remodeling18. Particularly, intimal 
hyperplasia, or arterial wall thickening, reduces the cross-sectional area of the lumen, or 
open space for blood to flow through. This type of arterial remodeling indicated in sickle 
cell is seen in other diseases such as atherosclerosis, except instead of plaques being 
filled with fatty material, it is filled with excess extracellular matrix18. 
The major protease that is responsible for arterial remodeling is cathepsin K, a cysteine 
protease that is capable of cleaving collagen in its native conformation19. It is considered 
to be the most potent mammalian collagenase and a very strong elastase20. By degrading 
the elastin within arterial walls, the structural integrity of the artery is compromised, and 
a combination of smooth muscle cell proliferation and matrix deposition thickens the 
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intima layer of the wall leading to a decrease in lumen area21. Cathepsin K is known to 
upregulated in plaques seen in atherosclerosis, and since there are strong parallels 
between these two types of arterial remodeling, there is a strong suggestion that cathepsin 
K plays a role in stroke lesion development in sickle cell disease as well22. 
Currently, there is only one drug on the market for alleviating some of the symptoms of 
sickle cell disease -  Hydroxyurea23. Still, this drug does not reduce the risk of stroke in 
these patients. Therefore, the purpose of this study is to understand the mechanistic 
relationships between the biological, biochemical, and biomechanical factors that 
regulate cathepsin K, which consequently regulates arterial remodeling. New insights 
gained from this deeper understanding may then be used to potentially discover new 




Materials and Methods 
 
Animal treatment and drug trial 
 
 Sickle (SS), sickle trait (AS), and normal (AA) mice were bred using the 
offspring of an AS male and an AS female mouse. Three week old AA, AS, and SS mice 
are to be given 50mg/kg injections of the cathepsin inhibitor Odanacatib twice a week for 
5 weeks. Mice are going to be euthanized with CO2 asphyxiation, and the carotid arteries, 
aorta, and brain are going to be isolated.  
Elastin staining on carotid arteries 
 
 The carotid arteries are going to be fixed in 4% paraformaldehyde and processed 
for paraffin sectioning. HistoGel-imbedded carotid arteries will be deparaffinized before 
staining. Elastin will be visualized using a modified Verhoeff elastic-van Gieson stain. 
Briefly, sections will be placed in a modified Verhoeff elastic for 7 minutes, and washed 
with warm water for 1 minute.  Samples will then be resolved in 0.4% ferric chloride, 
rinsed again with warm water for 5 minutes, and counter-stained with Van Geisons 
solution for 60 seconds.  Slides will be covered with a glass plate and imaged. 
Immunohistochemistry on carotid arteries for cathepsin K 
 
 To visualize cathepsin K expression, deparaffinized sections of carotid arteries 
will be permeabilized with 0.2% Triton, washed three times with PBS, followed by 
antigen retrieval using 0.1% trypsin.  Samples will be washed again three times with PBS 
and blocked with 2% bovine serum albumin (BSA) for 1 hour at room temperature. 
Cathepsin K will be visualized with a rabbit monoclonal anti-mouse primary antibody 
before tagging with AlexaFluorTM 488 secondary antibody and imaged.  
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Zymography and Western blots on Aortas for cathepsin K 
 
 Isolated and cleaned aortas will be grinded and lysed with a lysis buffer. The aorta 
lysates will be run through a modified SDS-PAGE protocol using a gelatin-based gel to 
quantify the activity of proteins, specifically cathepsin K. By using antibodies, specific 
proteins will be tagged for visualization with fluorescence through western blot. 
Examples of relevant protein are JNK, cathepsin K, and elastin.  
Magnetic Resonance Imaging (MRI) of mice brains 
 
 The brains are going to be fixed in 4% paraformaldehyde. The fixed brains will 
embedded in 2% agarose and imaged using 9.4 Tesla magnet resonance imaging scanner 




Systemic inhibition of cathepsin K decreases elastin fragmentation in sickle 
transgenic mice. 
 
 Elastin staining showed that SS mice treated with odanacatib had reduced elastin 
fraying and fewer elastin breaks compared to SS mice treated with vehicle (Fig 1A and 
C). Elastin fragmentation of SS mice treated with odancatib was equivalent to AS mice 
treated with vehicle (Fig 1A and B). In addition, there was no effect of odanacatib on 
elastin fragmentation on AS mice because there was no difference in elastin breaks and 











AS vehicle AS odanacatib 
SS vehicle SS odanacatib 
Figure 1 Odanacatib preserves elastin integrity in sickle transgenic mice. Carotid 
aortas were isolated from drug and placebo group animals, sectioned, and histologically 
stained for elastin morphology. Sickle transgenic animals receiving daily injections of 
odanacatib had substantially reduced incidence of elastin fragmentation compared to both 
trait and normal animals of sickle transgenic animals. 
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Systemic inhibition of cathepsin K activity has no effect on cathepsin K 
expression. 
 
 Immunohistochemical staining shows that odanacatib treatment has no effect on 
cathepsin K expression compared to vehicle in the carotid artery wall of sickle transgenic 
mice (Fig 2C and 2D). Contrarily, cathepsin K expression was not affected by odanacatib 
treatment in AS mice (Fig 2A and B). The reduction of cathepsin K expression by 
odanacatib on SS mice made the expression comparable to AS mice with and without 














Figure 2 Odanacatib decreases cathepsin K expression in sickle transgenic mice. 
Carotid aortas were isolated from drug and placebo group animals, sectioned, and 
immunostained for cathepsin K protein. Sickle transgenic animals receiving daily 
injections of odanacatib had similar staining for cathepsin K, compared to the placebo 
group of sickle transgenic animals. 
(C) SS vehicle (D) SS odanacatib 








 The present study evaluates the use of odanacatib for reduction of sickle cell-
mediated arterial pathologies. It has been shown that elastin fragmentation in sickle 
transgenic mice can be reduced with treatment with odanacatib treatment. It is interesting 
to see that while elastin fragmentation is decreased, cathepsin K expression levels are the 
same, if not slightly increased, in sickle cell transgenic mice treated compared to 
untreated. The reason cathepsin K expression is not decreased is because odanacatib is an 
activity-based inhibitor, so even though the protease is present, it is not active. In order to 
confirm this hypothesis, a western blot and zymography will be done to measure the 
amount and activity of cathepsin K present quantitatively. The reason why cathepsin K 
expression is increased in odanacatib treated sickle transgenic mice may be that the 
endothelial cells may be trying to compensate for the lack of perceived cathepsin K 
activity by upregulated the expression. In order to confirm this hypothesis, PCR would 
need to be done to measure the amount of cathepsin K mRNA present.  Further studies 
must also be done on the mice brains to test the hypothesis that odanacatib reduces the 





This study shows that odanacatib is effective in reducing the amount of elastin 
fragmentation in the carotid arteries. By preserving the structural integrity of the carotid 
arteries, the risk for strokes is believed to be reduced. While the expression of cathepsin 
K is shown to be similar to the control, odanacatib is an activity-based inhibitor, so it is 
suggested that although the protease is present, it is in its inactive form. With further 
research and validation, odanacatib may prove to be a great therapeutic drug to reduce the 
risk of stroke in people with sickle cell disease. 
 12 
REFERENCES 
1. Verduzco, L.A. & Nathan, D.G. Sickle cell disease and stroke. Blood 114, 
5117-5125 (2009). 
2. Barabino, G., McIntire, L., Eskin, S., Sears, D. & Udden, M. Endothelial cell 
interactions with sickle cell, sickle trait, mechanically injured, and 
normal erythrocytes under controlled flow, Vol. 70. (1987). 
3. Switzer, J.A., Hess, D.C., Nichols, F.T. & Adams, R.J. Pathophysiology and 
treatment of stroke in sickle-cell disease: present and future. The Lancet 
Neurology 5, 501-512 (2006). 
4. Garnero, P. et al. The Collagenolytic Activity of Cathepsin K Is Unique 
among Mammalian Proteinases. Journal of Biological Chemistry 273, 
32347-32352 (1998). 
5. Keegan, P.M., Surapaneni, S. & Platt, M.O. Sickle Cell Disease Activates 
Peripheral Blood Mononuclear Cells to Induce Cathepsins K and V 
Activity in Endothelial Cells. Anemia 2012, 7 (2012). 
6. Keegan, P., Wilder, C. & Platt, M. Tumor necrosis factor alpha stimulates 
cathepsin K and V activity via juxtacrine monocyte–endothelial cell 
signaling and JNK activation. Mol Cell Biochem 367, 65-72 (2012). 
7. Adams, R. et al. The Use of Transcranial Ultrasonography to Predict Stroke 
in Sickle Cell Disease. New England Journal of Medicine 326, 605-610 
(1992). 
8. Gauthier, J.Y. et al. The discovery of odanacatib (MK-0822), a selective 
inhibitor of cathepsin K. Bioorganic & Medicinal Chemistry Letters 18, 
923-928 (2008). 
9. INGRAM, V.M. Gene mutations in human haemoglobin: the chemical 
difference between normal and sickle cell haemoglobin. Nature 180, 
326-328 (1957). 
10. Barabino, G.A., Platt, M.O. & Kaul, D.K. Sickle cell biomechanics. Annu 
Rev Biomed Eng 12, 345-367 (2010). 
11. Cao, Z. & Ferrone, F.A. A 50th order reaction predicted and observed for 
sickle hemoglobin nucleation. J. Mol. Biol. 256, 219-222 (1996). 
 13 
12. Pathare, A. et al. Cytokine profile of sickle cell disease in Oman. Am J 
Hematol 77, 323-328 (2004). 
13. Kaul, D.K., Fabry, M.E. & Nagel, R.L. Microvascular sites and 
characteristics of sickle cell adhesion to vascular endothelium in shear 
flow conditions: pathophysiological implications. Proc Natl Acad Sci 
USA 86, 3356-3360 (1989). 
14. Switzer, J.A., Hess, D.C., Nichols, F.T. & Adams, R.J. Pathophysiology 
and treatment of stroke in sickle-cell disease: present and future. Lancet 
neurology 5, 501-512 (2006). 
15. Moser, F.G. et al. The spectrum of brain MR abnormalities in sickle-cell 
disease: a report from the Cooperative Study of Sickle Cell Disease. 
AJNR Am J Neuroradiol 17, 965-972 (1996). 
16. Wang, W. Neuropsychologic performance in school-aged children with 
sickle cell disease: A report from the Cooperative Study of Sickle Cell 
Disease. The Journal of Pediatrics 139, 391-397 (2001). 
17. Bridgers, W.H. Cerebral vascular disease accompanying sickle cell anemia. 
Am J Pathol 15, 353-362.355 (1939). 
18. Barabino, G., McIntire, L., Eskin, S. & Sears, D. Endothelial cell 
interactions with sickle cell, sickle trait, mechanically injured, and 
normal \ldots. Blood (1987). 
19. Turk, B., Turk, V. & Turk, D. Structural and functional aspects of papain-
like cysteine proteinases and their protein inhibitors. Biological 
Chemistry 378, 141-150 (1997). 
20. Dubin, G. Proteinaceous cysteine protease inhibitors. Cell. Mol. Life Sci. 
62, 653-669 (2005). 
21. Liu, J. et al. Cathepsin L expression and regulation in human abdominal 
aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis 184, 
302-311 (2006). 
22. Platt, M.O. et al. Expression of cathepsin K is regulated by shear stress in 
cultured endothelial cells and is increased in endothelium in human 
atherosclerosis. Am J Physiol Heart Circ Physiol 292, H1479-1486 
(2007). 
 14 
23. Ferster, A. et al. Five years of experience with hydroxyurea in children and 







Suhaas was born in Raleigh, North Carolina.  He attended public school high 
school in Naperville, IL, before coming to Georgia Tech to pursue a B.S. in Biomedical 
Engineering.  When he is not working on his research, Suhaas enjoys playing video 
games and going to the gym.  
 
 
